Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
such patients with regular and chronic ethanol consumption be monitored for the desired therapeutic response to vitamin B12
doi: 10.3389/fbioe.2026.1797044 Received 27 January 2026 Revised 28 February 2026 Accepted 12 March 2026 Published 01 April 2026 Volume 14 - 2026 Edited by Matteo Battaglini, Italian Institute of Technology (IIT), Italy Reviewed by Patrizia Guidi, University of Pisa, Italy Yuhong Nie, Sichuan No
10.1016/j.bbadis.2023.167014 43 HanK.LiJ.YinS.HuH.ZhaoC
13 In 1993, The Journal of Clinical Apheresis published a paper detailing the use of TPE as either a first- or second-line therapy to be used with other modalities on disorders such as Raynauds disease, systemic lupus erythematosus, coagulation factor inhibitors, familial hypercholesterolemia, acute Guillain-Barr syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, cryoglobulinemia, Goodpastures syndrome, and thrombotic thrombocytopenic purpura
